GSK9311
SIGMA/SML1984 - ≥98% (HPLC)
Synonym: (R)
CAS Number: 1923851-49-3
Empirical Formula (Hill Notation): C24H31N5O3
Molecular Weight: 437.53
MDL Number: MFCD31382186
Linear Formula: C24H31N5O3
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI key | WFXIHQFRQPGCCR-MRXNPFEDSA |
| optical activity | [α]/D 90 to 100°, c = 0.3 in methanol |
| SMILES string | O=C1N(C)C2=CC(N3CCNC[C@H] |
| solubility | DMSO: 2 mg/mL, clear (warmed) |
| storage temp. | −20°C |
| Biochem/physiol Actions: | GSK9311 is a negative control for the SGC epigenetic probe GSK6853 . GSK9311 exhibits 125- and 185-fold reduced potency than its structural analog GSK6853 toward BRPF1 in cell-free and cell-based assays (pIC50 = 6.0/GSK9311 vs. 8.1/GSK6853 in ligand competition binding assay by TR-FRET; IC50 = 3.7 μM/GSK9311 vs. 20 nM/GSK6853 against NanoLuc-BRPF1 bromodomain interaction with Histone H3.3-HaloTag in HEK293 cells), and therefore serves as a good inactive control compound in BRPF1 inhibition studies employing GSK6853. For characterization details of the active probe, GSK6853, please visit the GSK6853 probe summary ![]() GSK6853, the active probe, is available from Sigma. To learn more about and purchase GSK6853, click here .To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc ![]() |
| Biochem/physiol Actions: | Less potent control compound for GSK6853 in BRPF1 inhibition studies. |
| Features and Benefits: | GSK9311 is the negative control for GSK6853, an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit sigma.com/SGC . |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352202 |

. GSK9311 exhibits 125- and 185-fold reduced potency than its structural analog GSK6853 toward BRPF1 in cell-free and cell-based assays (pIC50 = 6.0/GSK9311 vs. 8.1/GSK6853 in ligand competition binding assay by TR-FRET; IC50 = 3.7 μM/GSK9311 vs. 20 nM/GSK6853 against NanoLuc-BRPF1 bromodomain interaction with Histone H3.3-HaloTag in HEK293 cells), and therefore serves as a good inactive control compound in BRPF1 inhibition studies employing GSK6853. For characterization details of the active probe, GSK6853, please visit the